The case that follows is to our knowledge the first report of successful cytokine-stimulated mobilization and collection of PBSCs followed by autologous peripheral blood hematopoietic stem cell transplant for an aggressive hematologic malignancy in a patient with a concomitant chronic myeloproliferative neoplasm. In 2007, a 51-yearold man developed large extremity hematomas without precipitating trauma. Complete blood count revealed a plt count of 716 000 without anemia or leukocytosis. Coagulation studies showed a low ristocetin cofactor of 43% and low von Willebrand Ag of 59% with normal multimer distribution. BM biopsy was performed, given suspicion of a myeloproliferative neoplasm, and it showed 60% cellularity with megakaryocytic hyperplasia and clustering with no increased blasts. Unexpectedly, clusters of plasma cells accounting for 20% of the marrow cellularity were also identified ( Figure 1 ) and found to be l-light chain restricted. Conventional cytogenetics revealed a normal karyotype, but fluorescence in situ hybridization showed trisomy 3, 7, 9, 11 and 15, indicative of a hyperdiploid plasma cell clone. JAK2 V617F mutation analysis was also positive with a low allele burden. Skeletal survey showed numerous lytic lesions throughout the axial and appendicular skeleton. He did not have palpable splenomegaly. The patient was diagnosed with Durie-Salmon stage IIA multiple myeloma and concomitant essential thrombocythemia with acquired von Willebrand syndrome. He received two cycles of pulse dexamethasone as initial multiple myeloma therapy. He tolerated this well, although his plt count rose to over 900 000. He then received bortezomib and dexamethasone (thalidomide and analogues were not considered because of thrombosis risk) for further cytoreduction, to which he showed a very good partial response. Next, he underwent stem-cell mobilization using granulocyte colony-stimulating factor priming, yielding 13 Â 10 6 CD34 þ cells/kg despite focal areas of 2 þ marrow reticulin fibrosis without difficulty or complications. He had no bleeding complications from his central venous line placement. Pre-peripheral blood hematopoietic stem cell transplant conditioning was with full dose melphalan at 200 mg/m 2 . On day 0, he received 4.47 Â 10 6 CD34 cells/kg. By day þ 100, he had achieved a complete hematological response from his multiple myeloma, although features of essential thrombocythemia were still identifiable in the marrow. Hemorrhagic diathesis testing has not been repeated because the patient has not developed further hematomas since beginning the therapy for his myeloma. Our patient did not suffer any hemorrhagic or thrombotic sequelae from his myeloproliferative neoplasm during the stem cell collection process, in the peri-transplant period, nor in the subsequent period, and he remains in CR from his multiple myeloma over 2 years post-autologous peripheral blood hematopoietic stem cell transplant.
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